Literature DB >> 25203107

Multiple sclerosis: a review of the disease and treatment options.

Daniel Sturm1, Samuel L Gurevitz, Amelia Turner.   

Abstract

OBJECTIVE: To provide a review of the etiology, epidemiology, clinical features, diagnostic findings, and treatment options for multiple sclerosis (MS). DATA SOURCES: A PubMed search of English language articles using a combination of words: elderly; multiple sclerosis*, late onset multiple sclerosis*, etiology; screening; diagnosis; or treatment to identify original studies, guidelines, and reviews on multiple sclerosis and late-onset multiple sclerosis, published 2002 to 2013. Primary sources were then used to search for additional relevant material. STUDY SELECTION AND DATA EXTRACTION: Original studies, clinical reviews, references, and guidelines were obtained and evaluated for their clinical relevance. DATA SYNTHESIS: The literature included guidelines and considerations for the etiology, diagnosis, screening, and management of MS.
CONCLUSION: MS is a chronic autoimmune disease characterized by inflammation, demyelination, and local axonal injury. It typically presents between ages 20 and 40 and largely affects women. However, 2% to 10% of individuals are diagnosed after 50 years of age. Diagnosis is based on presentation of clinical symptoms and the McDonald criteria for diagnosing MS. Management focuses on suppression of the immune system and prevention of relapses.

Entities:  

Mesh:

Year:  2014        PMID: 25203107     DOI: 10.4140/TCP.n.2014.469

Source DB:  PubMed          Journal:  Consult Pharm        ISSN: 0888-5109


  8 in total

Review 1.  Formulary Drug Review: Ocrelizumab.

Authors:  Zaynah K Ali; Danial E Baker
Journal:  Hosp Pharm       Date:  2017-09-17

Review 2.  Impact of the Autonomic Nervous System on the Skeleton.

Authors:  Florent Elefteriou
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 3.  Impaired Neurovisceral Integration of Cardiovascular Modulation Contributes to Multiple Sclerosis Morbidities.

Authors:  Zohara Sternberg
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

Review 4.  Genetic, Epigenetic, and Environmental Factors Influencing Neurovisceral Integration of Cardiovascular Modulation: Focus on Multiple Sclerosis.

Authors:  Zohara Sternberg
Journal:  Neuromolecular Med       Date:  2015-10-26       Impact factor: 3.843

5.  Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.

Authors:  Deidre J Devier; Jesus F Lovera; Walter J Lukiw
Journal:  Front Mol Neurosci       Date:  2015-03-02       Impact factor: 5.639

6.  Astragaloside IV inhibits microglia activation via glucocorticoid receptor mediated signaling pathway.

Authors:  Hong-Shuai Liu; Hai-Lian Shi; Fei Huang; Karin E Peterson; Hui Wu; Yun-Yi Lan; Bei-Bei Zhang; Yi-Xin He; Tyson Woods; Min Du; Xiao-Jun Wu; Zheng-Tao Wang
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

Review 7.  Neurodegeneration in Multiple Sclerosis: The Role of Nrf2-Dependent Pathways.

Authors:  Paloma P Maldonado; Coram Guevara; Margrethe A Olesen; Juan Andres Orellana; Rodrigo A Quintanilla; Fernando C Ortiz
Journal:  Antioxidants (Basel)       Date:  2022-06-10

Review 8.  What's new in multiple sclerosis?

Authors:  Erika E Tillery; Jennifer N Clements; Zach Howard
Journal:  Ment Health Clin       Date:  2018-03-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.